ImmunoMet Therapeutics
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2450 Holcombe Blvd, Houston, Texas, 7702...Phone Number
(346) 772-0318Website
www.immunomet.comRevenue
$10.1 MillionIndustry
About ImmunoMet Therapeutics
ImmunoMet Therapeutics is a clinical-stage oncology company focused on developing novel cancer drugs by targeting metabolic dependencies in resistant tumors. Their lead asset, lixumistat (IM156), is a best-in-class OxPhos inhibitor that aims to improve treatment options for patients with advanced pancreatic cancer. The company has shown promising early results in clinical trials, particularly at MD Anderson Cancer Center, with a notable response rate in patients. ImmunoMet Therapeutics seeks to engage with investors and partners to further advance their innovative therapies in the oncology market.Explore more
ImmunoMet Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to ImmunoMet Therapeutics
Compare insights from companies similar to ImmunoMet Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ImmunoMet Therapeutics Tech Stack
A closer look at the technologies used by ImmunoMet Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ImmunoMet Therapeutics
Sign Up For FreeTo access detailed company insights
ImmunoMet Therapeutics is a clinical-stage oncology company focused on developing novel cancer drugs by targeting metabolic dependencies in resistant tumors. Their lead asset, lixumistat (IM156), is a best-in-class OxPhos inhibitor that aims to improve treatment options for patients with advanced pancreatic cancer. The company has shown promising e... Read More
